Please mail photos, text, audio cassette or video as applicable to
PPH Cure Foundation
1735 Connecticut Ave., NW
3rd. Floor
Washington, DC 20009
New Drug Trials
The Liu Center for Pulmonary Hypertension is involved in a dose-ranging study of
a new experimental drug for PPH that is similar to prostacyclin. HOWEVER, this drug
has a longer half-life, is stable at body temperature for several days and therefore,
has the potential for dosage without using an intravenous catheter (continuous subcutaneous
dosing). Results from this study will provide important information on the feasibility
of developing this drug for long term administration.
This study is sponsored by United Therapeutics
Corporation a company begun by former Glaxo Wellcome staff who developed
Flolan. The study will compare the acute hemodynamic and safety profiles of this
new drug compared to Flolan. This study can be carried out at the same time that
a patient is evaluated for chronic prostacyclin therapy. For more information, call
our research coordinator, Joy Beckmann at 310-222-3560.
Home
